... of cyclophosphamide. Results: The maximum tolerated dose was established at 9.0 mg/m 2 on a 5-day regimen, analogously to what was reported for topotecan monotherapy. One toxic death from septic shock and multiorgan failure occurred. Although hematopoietic toxicities were overcome by peripheral blood stem cell...

...Markus Porsch; Matthias Ulrich; Johann Jakob Wendler; Uwe-Bernd Liehr; Frank Reiher; Andreas Janitzky; Daniel Baumunk; Daniel Schindele; Florian Seseke; Anke Lux; Martin Schostak Background: Docetaxel plus prednisone is a standard treatment for castration-resistant prostate cancer. Cyclophosphamide...

...Marie Hanaoka; Hidetaka Kawabata; Tsuguo Iwatani; Toshimi Takano; Daishu Miura Background: This retrospective study aimed to determine whether adverse events are more common in docetaxel followed by cyclophosphamide (TC) as compared to the reverse infusion order (rTC). Methods: A retrospective...

...Premila Abraham; Suganthy Rabi Background: Cyclophosphamide (CP) is an antineoplastic agent that is used for the treatment of many neoplastic diseases. Renal damage is one of the dose-limiting side effects of CP. Recent studies show that nitrosative stress plays an important role in CP-induced...

...Amal G. Fatani; Amal Q. Darweesh; Lubna Rizwan; Abdulaziz M. Aleisa; Othman A. Al-Shabanah; Mohamed M. Sayed-Ahmed Background: This study examined, for the first time, the involvement of carnitine deficiency in cardiotoxicity, particularly cyclophosphamide (CP)-induced cardiomyopathy, as well...

...S. Subramaniam; Shyama Subramaniam; M. Jagadeesan; Shyamala Devi Most of the breast cancer patients are treated with CMF which is a combination of three anticancer agents namely cyclophosphamide, methotrexate and 5-fluorouracil. The metabolites of CMF induce the level of lipid peroxides...

...P. Pronzato; G. Bertelli; D. Amoroso; C. Pennucci; G. Gardin; T. Guido; P. Rosso An oral chemotherapy schedule based on idarubicin and cyclophosphamide was evalutated in 31 advanced breast cancer patients. Out of 27 patients evaluable for response, 1 (3.7%) achieved a complete response and 5 (18.5...

... are described. Examination of the histology and of the water content of the tumor confirmed that a high-dose cyclophosphamide monotherapy can cause severe necrosis in the tumor and its seeded lung metastases. A significant decrease in tumor volume of 50% (p ≤ 0.01) was provoked and increased the mean survival...

...Giovanni Codacci-Pisanelli; Fabrizio Franchi; Antonella Afeltra; Franca Simone; Lorenzo Bonomo High-dose cyclophosphamide can be used to obtain haema-tological stem cells from the peripheral blood. In this paper we analyse the dynamics of appearance of cells with these characteristics, together...

...Jayasree Ghosh; Sukta Das The effect of deficiency of vitamin A and its supplementation on growth of murine sarcoma 180 was evaluated. The efficacy of cyclophosphamide under depleted and supplemented condition of the vitamin was also scrutinized. Supplemental vitamin A helped to check progression...

...Alan B. Weitberg Twenty-five evaluable patients with non-small cell carcinoma of the lung were treated with cyclophosphamide, vindesine and oral VP-16 in the outpatient setting. The overall response rate was 44% and the median survival was 4.9 months (7.25 months in responders). 9 9 2009...

...Eiichi Furusawa; Shinobu Furusawa Adverse (tumor-enhancing) effects of cyclophosphamide at moderate dose (50 mg/kg) given therapeutically were confirmed on the intraperitoneally implanted Lewis lung carcinoma (LLC) in allogeneic DBA/2 and BALB/c mice. It was recently demonstrated that antitumor...

... Corynebacterium isolates, as were mice pretreated with cyclophosphamide (leukopenia), type II Carrageenan (blockade of macrophages), or zymosan (depletion of complement), or with the combination of cyclophosphamide plus zymosan. However, mice pretreated with cyclophosphamide plus type II Carrageenan proved...

... 2 ) cis-platinum (DDP) in combination with cyclophosphamide (600 mg/m 2 ) had a significantly higher response and survival rate than the low-dose DDP (60 mg/m 2 ) and cyclophosphamide combination. The 3-year actuarial survival rate of the high-dose group was 60% and that of the low-dose group was 30...

..., combinations of cis -Pt(II) plus cyclophosphamide, isophosphamide, 1,2-bis(3,5-dioxopiperazine-1-yl)ρropane [ICRF-159] or emetine elicited increases in life-span at least double those achieved with the more effective of the individual drugs. Combinations of cis -Pt(II) plus 9 other antileukemic drugs showed...

...S. Vadlamudi; M. Padarathsingh; V.S. Waravdekar; A. Goldin Investigations were conducted to characterize the antileukemic (L1210) activity of 2 related dimethanesulfonates, and to compare the activity with that of cyclophosphamide. A single treament on day 2 with 108 mg/kg of 1-propanol, 3,3...